Login
Register
DEFINING TOMORROW'S VASCULAR STRATEGIES
DEFINING TOMORROW'S VASCULAR STRATEGIES
×
Register now to R3i !
Become a member to receive our newsletter and get unrestricted access to downloadable slidekits...
| Your login | |
| Your password | |
| Confirm your password | |
| Your email | |
| I agree to receive the R3i newsletter | |
Already registered?
Neved registered?
Forgot your codes?
Focus on selected Residual Risk publications
Each year, more than 100 papers related to atherogenic dyslipidemia, macrovascular events or microvascular complications of diabetes are published in major journals all around the world.
Each month, the R3i will select a valuable article and comment its most interesting aspects.
Each month, the R3i will select a valuable article and comment its most interesting aspects.
-
12 March 2024Comorbid microvascular disease in patients with peripheral artery disease: an escalating issue
-
8 January 2024Elevated lipoprotein(a) and coronary risk in acute coronary syndrome patients
-
26 September 2023Managing remnant cholesterol: consider both accumulation and visit variability
-
6 July 2023Lipid control in high-risk patients: women still lag behind men
-
13 April 2023Elevated triglycerides, a prevalent identifier of high cardiovascular risk
-
6 December 2022RESPECT-EPA– Randomized Trial for Evaluating Secondary Prevention Efficacy of Combination Therapy - Statin and Eicosapentaenoic Acid
-
21 September 2022News from TRANSLATE-TIMI 70 with vupanorsen, ANGPLT3 antisense oligonucleotide
-
19 July 2022Elevated lipoprotein(a) promotes progression of vulnerable plaque
-
21 February 2022Triglycerides and mortality risk in diabetes
-
2 November 2021New study makes the case for identifying remnant cholesterol-related residual risk in primary prevention
-
7 September 2021PESA study: elevated triglycerides associate with subclinical atherosclerosis
-
9 August 2021Direct or calculated remnant cholesterol: does it matter?
-
21 May 2021Identifying residual cardiovascular risk: which are the best lipid biomarkers?
-
26 April 2021Low HDL cholesterol and risk for severe COVID-19 infection
-
22 March 2021Triglycerides, dementia and atherosclerotic cardiovascular disease
-
16 February 2021PREDIMED shows association between remnant cholesterol and incident cardiovascular disease
-
4 January 2021Empagliflozin reduced the total burden of cardiovascular complications in type 2 diabetes patients with cardiovascular disease
-
5 October 2020Vupanorsen, an N-acetyl galactosamine-conjugated ANGPTL3 antisense drug, shows promise
-
20 July 2020Lipoprotein(a): a marker of residual cardiovascular risk
-
2 June 2020Insights from the Women’s Health Study: Cholesterol in triglyceride-rich lipoproteins strongly associates with incident cardiovascular disease
-
19 March 2020Meta-analysis: Association between triglyceride lowering and reduction of cardiovascular risk
-
17 February 2020Real world data: Hypertriglyceridemia is common among patients with cardiovascular disease and confers higher cardiovascular risk
-
19 December 2019ANGPTL3 monoclonal antibody in hypertriglyceridemia
-
19 July 2019Remnant cholesterol and risk of ischaemic stroke
-
6 November 2018More evidence linking remnants with cardiovascular disease
-
12 July 2018APOA5 genetic variability, triglycerides and coronary heart disease risk in Chinese subjects
-
27 April 2018Quantifying residual risk on long-term lipid-lowering therapy
-
13 February 2018Remnant cholesterol: a novel target for reducing lipid-related residual cardiovascular risk
-
10 January 2018Triglycerides in risk prediction in primary prevention
-
4 December 2017Nonfasting triglycerides and heart failure risk
-
16 October 2017Atherogenic lipoproteins and residual cardiovascular risk: the role of triglyceride-rich lipoproteins
-
28 July 2017Novel therapeutics for managing elevated triglycerides by targeting angiopoietin-like 3 (ANGPTL3)
-
22 June 2017Position paper on atherogenic dyslipidaemia in Latin America
-
24 April 2017High mortality risk in ischaemic stroke patients in Arab countries
-
28 February 2017REMAIN study highlights residual dyslipidaemia in acute coronary syndrome Indian patients
-
13 December 2016PROMINENT (Pemafibrate to Reduce cardiovascular OutcoMes by reducing triglycerides IN diabetic patiENTs): A rationale
-
14 October 2016Remnant cholesterol and decreased myocardial function in type 2 diabetes
-
18 September 2016New analysis supports targeting non-HDL cholesterol, triglycerides to reduce plaque progression
-
22 August 2016Atherogenic dyslipidaemia and silent coronary artery disease in type 2 diabetes
-
19 July 2016K-877, a novel SPPARM? agent, for reducing atherogenic lipoproteins: Phase II results
-
13 June 2016Genetic study provides support for targeting atherogenic cholesterol beyond that carried by LDL particles to reduce residual cardiovascular risk
-
15 May 2016Symptomatic polyneuropathy more common with increasing number of metabolic syndrome components
-
15 April 2016Genetic studies indicate potential of ANGPTL4 inhibition for lowering triglycerides and preventing coronary disease
-
15 March 2016Elevated remnant cholesterol: a contributor to residual mortality risk in high-risk patients
-
12 February 2016New genetic insights: PCSK7 linked with triglycerides
-
11 January 2016Visceral adipose tissue predicts development of atherogenic dyslipidaemia
-
8 December 2015Multifactorial approach the key to managing high cardiovascular risk
-
6 November 2015Novel antisense apolipoprotein(a) agent offers new potential for targeting lipid-related residual cardiovascular risk
-
8 October 2015Targeting the gut microbiome: potential for managing atherogenic dyslipidaemia?
-
4 September 2015Triglyceride-rich lipoprotein cholesterol: how to calculate from nonfasting samples?
-
8 July 2015Targeting apolipoprotein CIII: potential for reducing cardiovascular risk in type 2 diabetes
-
8 June 2015MULTI-GAP: Non-high-density lipoprotein cholesterol goal attainment and elevated triglycerides
-
18 May 2015Utility of triglycerides/HDL-C ratio in acute coronary syndrome patients
-
13 April 2015Hint of outcomes benefit with PCSK9 inhibition
-
9 March 2015Do emerging risk factors contribute to residual cardiovascular risk?
-
8 February 2015Non-fasting triglycerides: a predictor of ischaemic cardiovascular risk in Japanese subjects
-
5 January 2015Peroxisome proliferator-activated receptor alpha (PPARα) and its role in diabetic retinopathy: Novel insights
-
1 December 2014Hypertriglyceridaemia: the clinical and economic burden of undertreatment
-
3 October 2014PCSK9 inhibition in the corner: new data on safety and efficacy
-
13 June 2014APOC3: a potential target for residual cardiovascular risk?
-
13 May 2014New potential for non-alcoholic fatty liver disease?
-
13 March 2014Lipoprotein(a): overlooked component of residual cardiovascular risk?
-
13 February 2014REALIST-Micro: Diabetic microvascular complications associated with atherogenic dyslipidaemia
-
13 January 2014FinnDiane study: atherogenic dyslipidaemia and diabetic retinopathy in type 1 diabetes
-
5 December 2013New meta-analysis links triglycerides with cardiovascular and all-cause mortality
-
5 November 2013New genetic study highlights causal role of triglyceride-rich lipoproteins in coronary artery disease
-
8 October 2013Triglyceride-rich lipoproteins associate with unstable carotid plaque
-
1 September 2013Fibrates and adiponectin: pleiotropic effects on residual cardiovascular risk?
-
1 July 2013LoDoCo trial: Low-dose colchicine reduces the residual risk of acute coronary syndrome (ACS) events in secondary prevention patients
-
1 June 2013NHANES: atherogenic dyslipidemia is suboptimally treated
-
5 January 2013Triglyceride-rich lipoproteins: mediator of the association between chronic kidney disease and CVD
-
4 January 2013HPS2-THRIVE: niacin NOT the answer for residual cardiovascular risk
-
2 May 2013New from the PREDIMED study: Mediterranean diet for primary prevention of cardiovascular disease
-
1 January 2013Remnant cholesterol: a causal factor in coronary disease
-
7 December 2012Targeting atherogenic dyslipidemia to reduce residual microvascular risk
-
12 January 2012Meta-analysis: Targeting atherogenic dyslipidemia with a fibrate can reduce residual vascular risk in chronic kidney disease
-
15 November 2012Regular egg consumption: a hidden residual risk factor to be considered in high-risk patients
-
10 October 2012New data from ADVANCE: Low HDL cholesterol is an independent predictor of diabetic nephropathy in type 2 diabete
-
12 June 2012Triglyceride-HDL cholesterol ratio: a prognostic role in microvascular complications of type 2 diabetes?
-
1 November 2011The AIM-HIGH trial: residual macrovascular risk not reduced by extended-release niacin but was the objective too ambitious?
-
1 January 2011High-dose statins and risk of new-onset diabetes
-
1 January 2011Fenofibrate exerts renoprotective effects in patients with type 2 diabetes
-
20 March 2011Cholesterol efflux capacity – A metric of HDL function and a strong inverse predictor of risk of atherosclerosis and coronary events
-
28 July 2010Intensive blood pressure control in type 2 diabetes: the Blood Pressure Treatment arm of the ACCORD* study
-
28 July 2010Lipid targets beyond LDL-C for predicting residual coronary risk: the EPIC*-Norfolk study
-
1 May 2010Effect of blood pressure lowering and intensive glucose control on retinopathy in patients with type 2 diabetes mellitus
-
1 January 2010Reducing residual microvascular risk in diabetes: an unmet clinical priority. A review of the evidence implicating atherogenic dyslipidemia
-
12 July 2005In coronary heart disease patients treated with conventional- or high-dose statins, plasma triglycerides predict residual risk of cardiovascular events
-
15 November 2009Raising HDL-C and lowering triglycerides further to intensive LDL-C lowering in patients at LDL-C goal. Findings and issues raised by ARBITER 6-HALTS
-
26 October 2009Statin therapy in people with elevated hsCRP but without elevated LDL-C Findings and issues raised by the JUPITER trial
-
26 October 2009Elevated triglycerides levels accelerate progression of diabetic neuropathy in type 1 and type 2 diabetes
-
1 August 2009Beyond statin titration: Additional treatment approaches are needed to further reduce the risk of coronary events – The CALIPSO study
-
1 July 2009High prevalence of low HDL cholesterol and hypertriglyceridemia in treated dyslipidemic patients
-
1 May 2009The PRIME study: both statins and fibrates reduce 10-year mortality in dyslipidemic subjects
-
14 August 2008Stroke prevention: a major public health challenge in elderly Spanish individuals The PREV-ICTUS trial
-
12 September 2008Nonfasting triglycerides predict risk of ischemic stroke in a Danish population cohort Results from the Copenhagen City Heart Study
-
1 November 2008Most adult patients with CVD are not at recommended levels for all lipids – NHANES 2003-2004
-
2 October 2008Apolipoproteins as markers for residual risk reduction of myocardial infarction - INTERHEART
